1. Median overall survival was 11.5 months in the tisotumab vedotin group and 9.5 months in the chemotherapy group, with...

1. The complete response rates (pathological and clinical) were similar (~55%) in both groups. 2. Grade 3-4 adverse events rates...

1. The progression-free survival between the amivantamab–lazertinib group (23.7 months) and the osimertinib group (16.6 months) had an HR 0.70....

1. Subcutaneous amivantamab combined with lazertinib was non-inferior to intravenous amivantamab with lazertinib in terms of efficacy in treating refractory...

1. Patients with no biochemical or radiographic evidence of progressive disease had a median treatment break of 20.3 months. 2....

1. Daratumumab in combination with bortezomib, thalidomide, and dexamethasone (D-VTd) as induction and consolidation therapy led to superior progression-free survival...

1. No disease recurrences were observed during the median follow-up time of 26.2 months. 2. Immune-related adverse events grade 3-4...

1. Treatment with osimertinib significantly improved progression-free survival, compared to placebo, in patients with unresectable stage III EGFR-mutated NSCLC 2....

1. The event-free survival at 12 months was 83.7% in the neoadjuvant group vs 57.2% in the adjuvant group. 2....

1. Asciminib demonstrated higher efficacy for the treatment of newly diagnosed CML than imatinib and second-generation TKI 2. Asciminib had...